# Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

> **NCT06496048** · PHASE3 · RECRUITING · sponsor: **Luye Pharma Group Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Relapsed Small Cell Lung Cancer

## Interventions

- **DRUG:** Lurbinectedin
- **DRUG:** Irinotecan
- **DRUG:** Lurbinectedin
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT06496048
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-14
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06496048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06496048, "Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06496048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*